Zobrazeno 1 - 10
of 95
pro vyhledávání: '"Lori S Friedman"'
Autor:
Sarah Nicol Lauder, Kathryn Smart, Veerle Kersemans, Danny Allen, Jake Scott, Ana Pires, Stefan Milutinovic, Michelle Somerville, Sean Smart, Paul Kinchesh, Elena Lopez-Guadamillas, Ellyn Hughes, Martin Scurr, Lori S Friedman, Bart Vanhaesebroeck, Awen Gallimore
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background Despite striking successes, immunotherapies aimed at increasing cancer-specific T cell responses are unsuccessful in most patients with cancer. Inactivating regulatory T cells (Treg) by inhibiting the PI3Kδ signaling enzyme has shown prom
Externí odkaz:
https://doaj.org/article/03253b8693d64d3c84a6f9eeb342088e
Autor:
Jeffrey J Wallin, Jane Guan, Kyle A Edgar, Wei Zhou, Ross Francis, Anthony C Torres, Peter M Haverty, Jeffrey Eastham-Anderson, Sabrina Arena, Alberto Bardelli, Sue Griffin, John E Goodall, Kyla M Grimshaw, Klaus P Hoeflich, Christopher Torrance, Marcia Belvin, Lori S Friedman
Publikováno v:
PLoS ONE, Vol 7, Iss 5, p e36402 (2012)
The PTEN/PI3K pathway is commonly mutated in cancer and therefore represents an attractive target for therapeutic intervention. To investigate the primary phenotypes mediated by increased pathway signaling in a clean, patient-relevant context, an act
Externí odkaz:
https://doaj.org/article/64952bf9ee0a4f75af0606c666386285
Autor:
Timothy R. Wilson, Mark R. Lackner, Lori S. Friedman, Ciara Metcalfe, Michael E. Goldberg, Ethan S. Sokol, Wei Zhou, Carol O'Brien, Heidi M. Savage, Heather M. Moore
Supplementary Figure S7: MCF-7 DOX-inducible ER-alpha overexpressing cells without DOX induction respond similarly to taselisib and/or fulvestrant as MCF-7 parental cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1323ac6db0d9fe0223a192df2d5d72c5
https://doi.org/10.1158/1535-7163.22505926.v1
https://doi.org/10.1158/1535-7163.22505926.v1
Autor:
Lori S. Friedman, Anwesha Dey, Donald S. Kirkpatrick, Steven T. Staben, Shiva Malek, Alan G. Olivero, Timothy P. Heffron, Laurent Salphati, Gail D. Lewis Phillips, Emile G. Plise, Jonathan Cheong, Jeffrey J. Wallin, Jane Guan, Nicholas Endres, Stephen Schmidt, Eric Stawiski, William F. Forrest, Lilian Phu, Rebecca Hong, Michelle A. Nannini, Deepak Sampath, Mark Merchant, Jason Oeh, Marc Hafner, Emily J. Hanan, Kyle A. Edgar, Kyung W. Song
RTK activity plays a key role in regulating p110a degradation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c3f61f91c6eba4539d57e9ffe438944
https://doi.org/10.1158/2159-8290.22540279
https://doi.org/10.1158/2159-8290.22540279
Autor:
Lori S. Friedman, Anwesha Dey, Donald S. Kirkpatrick, Steven T. Staben, Shiva Malek, Alan G. Olivero, Timothy P. Heffron, Laurent Salphati, Gail D. Lewis Phillips, Emile G. Plise, Jonathan Cheong, Jeffrey J. Wallin, Jane Guan, Nicholas Endres, Stephen Schmidt, Eric Stawiski, William F. Forrest, Lilian Phu, Rebecca Hong, Michelle A. Nannini, Deepak Sampath, Mark Merchant, Jason Oeh, Marc Hafner, Emily J. Hanan, Kyle A. Edgar, Kyung W. Song
PIK3CA is one of the most frequently mutated oncogenes; the p110a protein it encodes plays a central role in tumor cell proliferation. Small-molecule inhibitors targeting the PI3K p110a catalytic subunit have entered clinical trials, with early-phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fd67c192262a4b6f3e1d058d9266830
https://doi.org/10.1158/2159-8290.c.6549343
https://doi.org/10.1158/2159-8290.c.6549343
Autor:
Lori S. Friedman, Marcia Belvin, Deepak Sampath, Mark R. Lackner, Leanne Ross, Robert Kassees, Letitia Lensun, Sonal Patel, Jill M. Spoerke, Carol O'Brien, Daniel P. Sutherlin, Alan G. Olivero, Laurent Salphati, Jodie Pang, Jim Nonomiya, Cristina Lewis, John D. Lesnick, Leslie Lee, Wei Wei Prior, Megan Berry, Jane Guan, Kyle A. Edgar, Jeffrey J. Wallin
PDF file - 894K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::136e199abb6bc063918f64da058aa806
https://doi.org/10.1158/1535-7163.22496520
https://doi.org/10.1158/1535-7163.22496520
Autor:
Lori S. Friedman, Marcia Belvin, Deepak Sampath, Mark R. Lackner, Leanne Ross, Robert Kassees, Letitia Lensun, Sonal Patel, Jill M. Spoerke, Carol O'Brien, Daniel P. Sutherlin, Alan G. Olivero, Laurent Salphati, Jodie Pang, Jim Nonomiya, Cristina Lewis, John D. Lesnick, Leslie Lee, Wei Wei Prior, Megan Berry, Jane Guan, Kyle A. Edgar, Jeffrey J. Wallin
Alterations of the phosphoinositide-3 kinase (PI3K)/Akt signaling pathway occur broadly in cancer via multiple mechanisms including mutation of the PIK3CA gene, loss or mutation of phosphatase and tensin homolog (PTEN), and deregulation of mammalian
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::344448ff3a06fe2f5d7081d2a898c2c2
https://doi.org/10.1158/1535-7163.c.6535305
https://doi.org/10.1158/1535-7163.c.6535305
Autor:
Mark R. Lackner, Marcia Belvin, John Moffat, Garret M. Hampton, Lukas C. Amler, Lori S. Friedman, Kyung Song, Wei Zhou, Connie Ha, Karen Toy, Huifen Chen, Sherry Heldens, William F. Forrest, Robert Soriano, Peter M. Haverty, Klaus P. Hoeflich, Jill M. Spoerke, Carol O'Brien, Bonnie Liu, Georgia Hatzivassiliou
The RAS/RAF/MEK pathway is activated in more than 30% of human cancers, most commonly via mutation in the K-ras oncogene and also via mutations in BRAF. Several allosteric mitogen-activated protein/extracellular signal–regulated kinase (MEK) inhibi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07be02e8e9258d59fd0d5344faa763ab
https://doi.org/10.1158/1535-7163.c.6535320.v1
https://doi.org/10.1158/1535-7163.c.6535320.v1
Autor:
Mark R. Lackner, Marcia Belvin, John Moffat, Garret M. Hampton, Lukas C. Amler, Lori S. Friedman, Kyung Song, Wei Zhou, Connie Ha, Karen Toy, Huifen Chen, Sherry Heldens, William F. Forrest, Robert Soriano, Peter M. Haverty, Klaus P. Hoeflich, Jill M. Spoerke, Carol O'Brien, Bonnie Liu, Georgia Hatzivassiliou
PDF file - 451K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3923262ef522e46408ad2b4fe9b478f6
https://doi.org/10.1158/1535-7163.22496553
https://doi.org/10.1158/1535-7163.22496553
Autor:
Klaus P. Hoeflich, Mark X. Sliwkowski, Lori S. Friedman, Lesley J. Murray, Marcia Belvin, Bert Gunter, Nicholas Lewin-Koh, Jeffrey Eastham-Anderson, Peter M. Haverty, Tom Truong, Si Tuen Lee-Hoeflich, Wei Zhou, Evelyn Yao
Purpose: Oncogenic activation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway is prevalent in breast cancer and has been associated with resistance to HER2 inhibitors in the clinic. We therefore investigated the combinatorial activity o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47fd590db93aa99ce95ad46b18daa8e8
https://doi.org/10.1158/1078-0432.c.6517759.v1
https://doi.org/10.1158/1078-0432.c.6517759.v1